Compare GSK plc (GSK) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Linde PLC — how do they compare? GSK plc trades at $52.7 (market cap $101.34B), while Linde PLC trades at $518.34 (market cap $237.72B). The key difference: Linde PLC is far larger — about 2.3× GSK plc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | LIN | |
|---|---|---|
Market Cap | $101.34B | $237.72B |
Sector | Health | Basic Materials |
52-Week High | $61.18 | $546.64 |
52-Week Low | $36.20 | $389.38 |
Enterprise Value | $121.95B | $260.07B |
Dividend Yield | 3.49% | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Linde (LIN) trades at $522.54, down 0.29% on the day, with a bullish technical signal from moving averages and oversold RSI suggesting potential rebound. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $4.33 (beat), and robust profitability with a 20.44% net margin. Recent news highlights sustainability leadership and Q1 results showing 10% EPS growth.
Outlook remains positive given analyst consensus (85.7% buy ratings) and a $560 price target, though high valuation multiples (P/E 34.65) pose a risk if growth moderates. Key risks include rising debt-to-asset ratio (31.63% in 2025) and macroeconomic pressures on industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
